NCT06280820
Multi-Scale Analysis of Phenotypes in Heart Failure (MAP-HEART)
Enrolling by Invitation
Not specifiedAges 18+ObservationalNational Heart, Lung, and Blood Institute (NHLBI)Government-funded
~2,000 participants
Updated 2026-08-03 on ClinicalTrials.gov
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To study the association between multi-omics signatures with all-cause mortality
Measured over 10 years
Conditions
Where it's being run
1 sites across 1 statesVirginia1
Study leadership
- Veronique L Roger, M.D. · PRINCIPAL_INVESTIGATOR · National Heart, Lung, and Blood Institute (NHLBI)
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Clinical diagnosis of "active" HF documented by a cardiology provider's note in the medical record. Active HF is the presence of signs or symptoms that are deemed to be related to heart failure, as documented in the participants' medical records.
Able and willing to undergo the consent process and provide consent
Willing to comply with required study activities
18 years of age or older
Exclusion
History of ventricular assist device
History of cardiac transplant
Living or residing outside of the geographic location designated for the study at the time of enrollment
What this trial measures
- To study the association between multi-omics signatures with all-cause mortality10 years
The heterogeneous HF syndrome encompasses different and poorly defined entities. Multi-omics can improve its characterization and the prediction of mortality, which remains high. All-cause mortality will be analyzed as the time from enrollment to all-cause death.